Quince Therapeutics Inc
QNCX
Company Profile
Business description
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Contact
611 Gateway Boulevard
Suite 273
South San FranciscoCA94080
USAT: +1 415 910-5717
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,850.30 | 16.70 | 0.19% |
| CAC 40 | 7,754.55 | 16.13 | 0.21% |
| DAX 40 | 23,934.13 | 144.02 | 0.61% |
| Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
| FTSE 100 | 8,823.20 | 48.51 | 0.55% |
| HKSE | 24,069.94 | 151.47 | -0.63% |
| NASDAQ | 20,601.10 | 207.97 | 1.02% |
| Nikkei 225 | 39,839.57 | 53.67 | 0.13% |
| NZX 50 Index | 12,738.29 | 33.81 | 0.27% |
| S&P 500 | 6,279.35 | 51.93 | 0.83% |
| S&P/ASX 200 | 8,610.70 | 14.90 | 0.17% |
| SSE Composite Index | 3,461.15 | 6.36 | 0.18% |